Current Rheumatology Reports

, 15:358

Top 10 Developments in Lupus Nephritis

SYSTEMIC LUPUS ERYTHEMATOSUS (M PETRI, SECTION EDITOR)

DOI: 10.1007/s11926-013-0358-7

Cite this article as:
Chen, T.K. & Fine, D.M. Curr Rheumatol Rep (2013) 15: 358. doi:10.1007/s11926-013-0358-7
Part of the following topical collections:
  1. Topical Collection on Systemic Lupus Erythematosus

Abstract

Lupus nephritis affects up to 60 % of patients with systemic lupus erythematosus and is associated with worse clinical outcomes. Traditionally, it has been treated with high-dose immunosuppression consisting of cyclophosphamide and prednisone; however, recent trials have demonstrated mycophenolate mofetil as a safe and effective alternative for both induction and maintenance of disease. Other progress has been made in our understanding of the pathogenesis of lupus nephritis, outcomes in renal transplantation, and associations with genetic risk factors. This review highlights key developments in our understanding of lupus nephritis over the past decade.

Keywords

Lupus nephritis Kidney Proliferative lupus nephritis Membranous lupus nephritis Renal transplantation APOL1 Induction therapy Maintenance therapy Systemic lupus erythematosus SLE Mycophenolate mofetil Rituximab Treatment Multitargeted therapy Epidemiology 

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Division of NephrologyThe Johns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations